Working for a Strong Türkiye with the Productive Healthcare Model
29 January 2025
A Historic Milestone in Local Biotechnological API Production!
17 June 2025
Dr. Hasan Zeytin, CEO of Yerlika, recently shared insights into the company’s strategic vision and Türkiye’s ambitions in biopharmaceutical manufacturing during an exclusive interview with the prestigious GaBI Journal. Titled “Turkey’s biotech manufacturing ambitions: Yerlika’s strategic role,” the article underscores Yerlika’s pivotal contributions towards reducing Türkiye’s dependence on imported biologicals and strengthening local production capabilities.
In the interview, Dr. Zeytin highlights Yerlika’s state-of-the-art manufacturing facilities and its R&D-driven approach, which enable the company to produce high-value biological products including follow-on biosimilars, monoclonal antibodies, gene therapies and vaccines. Yerlika’s GMP-compliant production site, located in the Çerkezköy Organized Industrial Zone, serves both local and international partners by offering comprehensive CDMO and CMO services.
The article also showcases Yerlika’s wide-ranging expertise, from targeted biologics for rare diseases and adenovirus-based cancer vaccines to gene therapies and specialized dermocosmetic formulations. With an emphasis on scientific excellence, regulatory compliance, and global collaboration, Yerlika is actively positioning Türkiye as a rising hub for biotechnology innovation.
“Our goal is not only to manufacture high-quality biopharmaceuticals but to transform Türkiye into a global biotechnology center,” said Dr. Zeytin during the interview, emphasizing Yerlika’s unwavering commitment to innovation, quality, and strategic partnerships.
Read the full interview here:
Turkey’s biotech manufacturing ambitions: Yerlika’s strategic role – GaBI Journal
At Yerlika, we take pride in advancing Türkiye’s biopharmaceutical industry through cutting-edge technologies, scientific innovation, and a vision to provide better access to life-saving treatments worldwide. We remain dedicated to pushing the boundaries of biotechnology and shaping a healthier future for all
